CST9 Polyclonal Antibody, FITC Conjugated
Applications
Reactivity
| Overview | |
| Catalog # | bs-9217R-FITC-100uL |
| Product Name | CST9 Polyclonal Antibody, FITC Conjugated |
| Applications |
IF
|
| Reactivity | Human |
| Specifications | |
| Conjugation | FITC |
| Host | Rabbit |
| Source | KLH conjugated synthetic peptide derived from human CST9/Cystatin 9 |
| Clonality | Polyclonal |
| Isotype | IgG |
| Concentration | 1ug/ul |
| Purification | Purified by Protein A. |
| Storage Buffer | Aqueous buffered solution containing 0.01M TBS (pH 7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol. |
| Storage Condition | Store at -20C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles. |
| Target | |
| Gene ID | 128822 |
| Synonyms | M12; CLM; Cresp; Cst9; CST9_HUMAN; Cystatin 9 testatin; Cystatin like molecule; Cystatin-9; Cystatin-like molecule; Testatin. |
| Background | The cystatin superfamily is a well-established family of cysteine protease inhibitors. All true cystatins inhibit cysteine peptidases of the papain family, such as cathepsins, while some also inhibit legumain family enzymes. The CRES (cystatin-related epididymal spermatogenic) protein defines a new subgroup in the family 2 cystatins of the cystatin superfamily. CRES proteins lack two of the three consensus sites necessary for the cystatin inhibition of C1 cysteine proteases. Due to their expression patterns, it is likely that CRES proteins may perform unique and tissue-specific functions in the reproductive and neuroendocrine systems. As a member of the CRES subfamily, Cystatin 9, also designated CLM, is a 159 amino acid protein that is expressed in heart, placenta, lung, liver, skeletal muscle and pancreas. Cystatin 9 is thought to play a role in hematopoietic differentiation or inflammation. It has also been shown to be upregulated by LPS in some cancer cell lines, such as promyelocytic leukemia (HL-60) and myelomonocytic leukemia. |
| Application Dilution | |
| IF | WB1:300-5000 |
Frequently asked questions
Which applications is CST9 Polyclonal Antibody, FITC Conjugated (bs-9217R-FITC) validated for, and at what dilution?
bs-9217R-FITC is validated for WB (1:300-5000); IF(IHC-P) (1:50-200). These are recommended starting dilutions; optimal dilutions should be determined by the end user.
Which species does CST9 Polyclonal Antibody, FITC Conjugated (bs-9217R-FITC) react with?
Tested reactivity: Human.
How should bs-9217R-FITC be stored?
Store at -20C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles. Storage buffer: Aqueous buffered solution containing 0.01M TBS (pH 7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol.
What immunogen was used to raise CST9 Polyclonal Antibody, FITC Conjugated (bs-9217R-FITC)?
KLH conjugated synthetic peptide derived from human CST9/Cystatin 9
What are the excitation and emission wavelengths of the FITC conjugate (bs-9217R-FITC)?
FITC on bs-9217R-FITC: excitation / emission 494nm/518nm.